Multi-gene expression lentivirus as well as preparation method and application thereof

By constructing a multi-gene expression lentiviral vector and using the combination of genes such as hTERT and CDC6shRNA to specifically express them in tumor cells, the problem of single targets and major side effects of existing therapeutic methods is solved, and efficient inhibition of multiple cancer cells is achieved and tumor suppression effect.

CN118995641APending Publication Date: 2024-11-22QINGDAO ARTAI GENE CO LTD
View PDF 0 Cites 3 Cited by

Patent Information

Application Number
CN202310558281.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-17
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Existing cancer treatment methods such as PD-1, PD-L1 and CAR-T therapy have single targets and large treatment limitations, which are not effective for solid tumors. Traditional chemotherapy brings huge side effects and is difficult to effectively inhibit tumor growth.

Method used

A lentiviral vector with multigene expression was constructed, carrying the hTERT promoter, CDC6shRNA, CMV promoter, P16 gene, PTEN gene and P53 gene, and inhibits cancer cell proliferation and promotes its self-destruction through specific expression in tumor cells.

Benefits of technology

Efficient inhibition of a variety of cancer cells was achieved, significantly reducing tumor cell growth, and the tumor suppression rate reached 77.33%. By activating tumor suppressor genes, the cells were restored to normal regulation and restored to normal state.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118995641A_ABST
    Figure CN118995641A_ABST
Patent Text Reader

Abstract

The invention provides a multi-gene expression lentivirus as well as a preparation method, application and a corresponding pharmaceutical composition thereof. According to the invention, an hTERT promoter, a CDC6shRNA-CMV-P16-PTEN-P53 gene sequence, a CMV promoter, a P16 gene, a PTEN gene and a P53 gene sequence are inserted behind a restriction enzyme cutting site of a vector to obtain plasmids, the plasmids are transferred into an expression strain, the expression strain is cultured and screened to obtain a kanamycin-tolerant cloned strain, and the kanamycin-tolerant cloned strain is packaged after being shaken to obtain the hTERT-CDC6shRNA-CMV-P16-PTEN-P53 polygene expression lentivirus. The lentivirus disclosed by the invention is used for infecting human thyroid cancer cells B-CPAP (papillary), and experimental results show that the lentivirus can effectively inhibit proliferation of cancer cells.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of tumor gene therapy. Specifically, the present invention provides a multi-gene expression lentivirus and its preparation method and application. Background Art

[0002] Cancer is a major global public health problem, and the global cancer incidence has been growing in recent years. Cancer treatment is a global problem. Traditional treatments can only be performed through surgery, radiotherapy, and chemotherapy, which have serious side effects and bring great pain to patients. In recent years, with the development of precision medical technology, more and more available targets have been discovered, ushering in an era of precision cancer treatment. Although new therapies such as PD-1, PD-L1, and CAR-T continue to emerge, PD-1 and PD-L1 have a single target and great treatment limitations, and are not effective in treating solid tumors; CAR-T is mainly used for the treatment of leukemia, and the treatment method is systemically administered through the blood, which is not effective in treating solid tumors.

[0003] Lentivirus vectors (LVs) are gene therapy vectors developed based on HIV-1 (human immunodeficiency virus type I). Lentiviruses can infect cells in the active phase of mitosis, as well as cells that divide slowly and are in the terminal phase of division, including hematopoietic stem cells, neural stem cells, neurons at the end of differentiation, hepatocytes, etc. In in vitro cell culture experiments and in vivo transplantation experiments, the target gene introduced by the lentivirus vector can be expressed long-term and stably. In addition, the lentivirus vector does not express any HIV-I protein and has low immunogenicity. The modified lentivirus vector can accommodate about 10kb of exogenous genes, so most cDNAs can be cloned into the lentivirus vector. These advantages make the lentivirus vector an effective tool for in vivo and in vitro gene transfer. At present, the target gene of the lentivirus vector is generally constructed as a promoter plus a target gene. The number of bases of the exogenous gene is about 1000bp. As the research deepens, it is found that a single exogenous target gene cannot solve the problem, and it is necessary to add a composite exogenous gene to assist in solving this problem. Summary of the invention

[0004] This patent is to construct the artificially synthesized composite gene hTERT-CDC6shRNA-CMV-P16-PTEN-P53 (base number 5188bp) into a lentiviral vector. hTERT telomerase is an RNA-dependent DNA polymerase, whose core structure contains the necessary RNA structure, and is composed of the human telomerase catalytic subunit (hTERT) with reverse transcription activity and related proteins. The hTERT promoter region lacks TATA box and CAAT box, and its structure is a GC-rich CpG island. 181bp upstream of the transcription start site is the core promoter region, with multiple transcription factor binding sites. The expression of the hTERT gene is in a closed state in mature and differentiated human tissue cells, and the gene is activated at the transcriptional level in tumor cells. Therefore, the promoter of the hTERT gene can specifically guide the tumor gene to be expressed only in tumor cells. Cancer cells contain a large amount of CDC6 protein that is not found in normal cells, and the greater the cell division of cancer cells, the higher the content of CDC6 protein. The principle of using "CDC6shRNA active gene" focuses on the characteristic of "cancer has unlimited proliferation". It can eliminate a DNA replication factor called CDC6 that exists in common cancer cells, knock down CDC6 protein, and then repair the mechanism of action on the tumor suppressor gene Rb pathway through p16, and prompt cancer cells to stop proliferating at the beginning of the proliferation stage. Then it activates the PTEN and p53 genes, which are called the guardian of genes, to effectively lead cancer cells to self-destruction, and through the efficient penetration of lentivirus vector into cancer cells, the proto-oncogenes and mutated, missing or inactivated tumor suppressor genes are restored to their normal regulatory functions, and the cancer cells are restored to normal cells, thereby achieving the purpose of tumor suppression. Through the results of in vitro experiments, we found that this combination of compound genes has a significant anti-cancer effect.

[0005] On the one hand, the present application provides a multi-gene expression lentivirus, wherein the multi-gene expression lentivirus carries hTERT promoter, CDC6shRNA gene, CMV promoter, P16 gene, PTEN gene and P53 gene.

[0006] Furthermore, the hTERT promoter sequence is SEQ ID NO.2.

[0007] Furthermore, the CDC6shRNA gene sequence is SEQ ID NO.3.

[0008] Furthermore, the CMV promoter sequence is SEQ ID NO.4.

[0009] Furthermore, the P16 gene sequence is SEQ ID NO.5.

[0010] Furthermore, the PTEN gene sequence is SEQ ID NO.6.

[0011] Furthermore, the P53 gene sequence is SEQ ID NO.7.

[0012] Furthermore, the multi-gene expression lentivirus carries the hTERT-CDC6shRNA-CMV-P16-PTEN-P53 combination gene.

[0013] Furthermore, the hTERT-CDC6shRNA-CMV-P16-PTEN-P53 combined gene sequence is SEQ ID NO.1.

[0014] On the other hand, the present application provides the use of the above-mentioned multi-gene expression lentivirus in the preparation of drugs for treating cancer.

[0015] Furthermore, the cancer is thyroid cancer.

[0016] On the other hand, the present application provides a pharmaceutical composition comprising the above-mentioned multi-gene expressing lentivirus.

[0017] Furthermore, the pharmaceutical composition also includes a pharmaceutically acceptable excipient.

[0018] Furthermore, the pharmaceutical composition is in the form of an injection.

[0019] On the other hand, the present application provides a method for preparing the above-mentioned multi-gene expression lentivirus:

[0020] (1) inserting hTERT promoter, CDC6shRNA gene and CMV promoter, P16 gene, PTEN gene, and P53 gene sequences after the restriction site of the vector to obtain a plasmid;

[0021] (2) transferring the plasmid into the expression strain, culturing and screening the successfully transferred strain;

[0022] (3) Shake the successfully transferred strain obtained in step (2) to obtain

[0023] hTERT-CDC6shRNA-CMV-P16-PTEN-P53 multi-gene expression plasmid;

[0024] (4) Packaging the multi-gene expression plasmid described in step (3) to obtain hTERT-CDC6shRNA-CMV-P16-PTEN-P53 multi-gene expression lentivirus. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1This is the electrophoresis diagram of plasmid hTERT-CDC6shRNA-CMV-P16-PTEN-P53 (6 lanes);

[0026] Figure 2 Comparison of cell conditions after virus infection (left side is B-CPAP blank and right side is B-CPAP after virus infection);

[0027] Figure 3 Cell counts 72 hours after virus infection (the upper part is B-CPAP blank, the lower part is B-CPAP after virus infection). DETAILED DESCRIPTION

[0028] Example 1 Construction of hTERT-CDC6shRNA-CMV-P16-PTEN-P53 overexpression clone

[0029] Relevant gene sequences were retrieved from Genbank, and the CDC6 shRNA sequence was designed. The hTERT-CDC6 shRNA-CMV-P16-PTEN-P53 overexpression clone was constructed using the seamless cloning method.

[0030] Here are the steps:

[0031] The vector Plenty6.3 / V5-TOPO (abbreviated as D) (purchased from Thermo Fisher Scientific) was digested with restriction sites ClaI and MluI, upstream primer: aattcaaaattttatcgataagacaattcacaaacacagccc (SEQ ID NO.14) and downstream primer: actaaccggtacgcgttcagtctgagtcaggcccttc (SEQ ID NO.15), and the hTERT promoter, CDC6shRNA and CMV promoter, P16, PTEN, and P53 gene sequences were inserted to obtain the hTERT-CDC6shRNA-CMV-P16-PTEN-P53 plasmid.

[0032] step:

[0033] Vector enzyme digestion, enzyme digestion system preparation:

[0034]

[0035] (Note: Enzyme digestion reaction conditions: 37℃ / 3h);

[0036] Seamless cloning connection

[0037]

[0038] (Note: Seamless cloning and ligation reaction conditions: 37℃ / 30min)

[0039] Ligation product conversion and plate coating

[0040] Melt 50ul TOP10 competent cells on ice, take 5ul ligation product and competent cells and mix them; ice bath for 30min, heat shock in 42℃ water bath for 90sec, ice bath for 2min; transfer the transformation product to an EP tube containing 500ul non-resistant LB liquid culture medium, place in a shaker, and culture at 37℃, 180rpm for 30min; centrifuge the EP tube containing the transformed bacteria at 4000rpm for 2min; pour out the supernatant in the clean bench, leaving about 100ul culture medium to mix the precipitate, and evenly apply it on the LB-Kan+ resistance culture plate; turn the plate upside down and place it in a 37℃ bacterial incubator to culture overnight (12-16h). Pick a monoclonal colony from the above plate and place it in 6ml LB-Kan+ liquid culture medium, 37℃, 250rpm, and culture overnight (12-16h); extract plasmids, sequence and identify, and compare the sequencing results with the target gene sequence. The identification result is the correct plasmid.

[0041] The plasmid hTERT-CDC6shRNA-CMV-P16-PTEN-P53 was obtained.

[0042] The sequences involved:

[0043] hTERT-CDC6shRNA-CMV-P16-PTEN-P53 gene sequence, SEQ ID NO.1: agacaattcacaaacacagccctttaaaaaggcttagggatcactaaggggatttctagaagagcgacctgtaatcctaagtatttacaagacgaggctaacct ccagcgagcgtgacagcccagggagggtgcgaggcctgttcaaatgctagctccataaataaagcaatttcctccggcagtttctgaaagtaggaaaggttacatttaa ggttgcgtttgttagcatttcagtgtttgccgacctcagctacagcatccctgcaaggcctcgggagacccagaagtttctcgccccttagatccaaacttgagcaacc cggagtctggattcctgggaagtcctcagctgtcctgcggttgtgccggggccccaggtctggaggggaccagtggccgtgtggcttctactgctgggctggaagtcgg

[0044] gcctcctagctctgcagtccgaggcttggagccaggtgcctggaccccgaggttgccctccaccctgtgcg

[0045] ggcgggatgtgaccagatgttggcctcatctgccagacagagtgccggggcccagggtcaaggccgttgt

[0046] ggctggtgtgaggcgcccggtgcgcggccagcaggagcgcctggctccatttcccaccctttctcgacggg

[0047] accgccccggtgggtgattaacagatttggggtggtttgctcatggtggggacccctcgccgcctgagaacc

[0048] tgcaaagagaaatgacgggcctgtgtcaaggagcccaagtcgcggggaagtgttgcagggaggcactc

[0049] cgggaggtcccgcgtgcccgtccagggagcaatgcgtcctcgggttcgtccccagccgcgtctacgcgcct

[0050] ccgtcctccccttcacgtccggcattcgtggtgcccggagcccgacgccccgcgtccggacctggaggca

[0051] gccctgggtctccggatcaggccagcggccaaagggtcgccgcacgcacctgttcccagggcctccacat

[0052] catggcccctccctcgggttaccccacagcctaggccgattcgacctctctccgctggggccctcgctggcg

[0053] tccctgcaccctgggagcgcgagcggcgcgcgggcggggaagcgcggcccagacccccgggtccgcc

[0054] cggagcagctgcgctgtcggggccaggccgggctcccagtggattcgcgggcacagacgcccaggacc

[0055] gcgcttcccacgtggcggagggactggggacccgggcacccgtcctgccccttcaccttccagctccgcct

[0056] cctccgcgcggaccccgccccgtcccgacccctcccgggtccccggcccagccccctccgggccctccc

[0057] agcccctccccttcctttccgcggccccgccctctcctcgcggcgcgagtttcaggcagcgctgcgtcctgct

[0058] gcgcacgtgggaagccctggccccggccacccccgcgatgaattcgatgatccccaggcacttgctacca

[0059] gcaattcaagagattgctggtagcaagtgccttttttggaaaagctatcaagcttaattcggatccattaggcg

[0060] gccgcgtggataaccgtattaccgccatgcattagttattaatagtaatcaattacggggtcattagttcatagc

[0061] ccatatatggagttccgcgttacataacttacggtaaatggcccgcctggctgaccgcccaacgacccccg

[0062] cccattgacgtcaataatgacgtatgttcccatagtaacgccaatagggactttccattgacgtcaatgggtg

[0063] gagtatttacggtaaactgcccacttggcagtacatcaagtgtatcatatgccaagtacgccccctattgacgt

[0064] caatgacggtaaatggcccgcctggcattatgcccagtacatgaccttatgggactttcctacttggcagtac

[0065] atctacgtattagtcatcgctattaccatggtgatgcggttttggcagtacatcaatgggcgtggatagcggtttg

[0066] actcacggggatttccaagtctccaccccattgacgtcaatgggagtttgttttggcaccaaaatcaacggga

[0067] ctttccaaaatgtcgtaacaactccgccccattgacgcaaatgggcggtaggcgtgtacggtgggaggtcta

[0068] tataagcagagctggtttagtgaaccgtcagatccgcatggagccggcggcggggagcagcatggagcc

[0069] ttcggctgactggctggccacggccgcggcccggggtcgggtagaggaggtgcgggcgctgctggaggc

[0070] gggggcgctgcccaacgcaccgaatagttacggtcggaggccgatccaggtcatgatgatgggcagcgc

[0071] ccgagtggcggagctgctgctgctccacggcgcggagcccaactgcgccgaccccgccactctcacccg

[0072] acccgtgcacgacgctgcccgggagggcttcctggacacgctggtggtgctgcaccgggccggggcgcg

[0073] gctggacgtgcgcgatgcctggggccgtctgcccgtggacctggctgaggagctgggccatcgcgatgtc

[0074] gacggtacctgcgcgcggctgcggggggcaccagaggcagtaaccatgcccgcatagatgccgcgg

[0075] aaggtccctcagacatccccgataaattgtcgctcctcaaacaaactcttaactttgatttactcaaactg

[0076] gctggggatgtagaaagcaatccaggtccaatgacagccatcatcaaagagatcgttagcagaaacaaa

[0077] aggagatatcaagaggatggattcgacttagacttgacctatatttatccaaacattatgctatgggatttcct

[0078] gcagaaagacttgaaggcgtatacaggaacaatattgatgatgtagtaaggtttttggattcaaagcataaa

[0079] aaccattacaagatatacaatctttgtgctgaaagacattatgacaccgccaaatttaattgcagagttgcac

[0080] aatatccttttgaagaccataacccaccacagctagaacttatcaaacccttttgtgaagatcttgaccaatgg

[0081] ctaagtgaagatgacaatcatgttgcagcaattcactgtaaagctggaaagggacgaactggtgtaatgat

[0082] atgtgcatatttattacatcggggcaaatttttaaaggcacaagaggcccttagatttctatggggaagtaagg

[0083] accagagacaaaaagggagtaactattcccagtcagaggcgctatgtgtattattatagctacctgttaaag

[0084] aatcatctggattatagaccagtggcactgttgtttcacaagatgatgtttgaaactattccaatgttcagtggcg

[0085] gaacttgcaatcctcagtttgtggtctgccagctaaaggtgaagatatattcctccaattcaggacccacacg

[0086] acgggaagacaagttcatgtactttgagttccctcagccgttacctgtgtgtggtgatatcaaagtagagttctt

[0087] ccacaaacagaacaagatgctaaaaaaggacaaaatgtttcacttttgggtaaatacattcttcataccagg

[0088] accagaggaaacctcagaaaaagtagaaaatggaagtctatgtgatcaagaaatcgatagcatttgcagt

[0089] atagagcgtgcagataatgacaaggaatatctagtacttactttaacaaaaaatgatcttgacaaagcaaat

[0090] aaagacaaagccaaccgatacttttctccaaattttaaggtgaagctgtacttcacaaaaacagtagagga

[0091] gccgtcaaatccagaggctagcagttcaacttctgtaacaccagatgttagtgacaatgaacctgatcattat

[0092] agatattctgacaccactgactctgatccagagaatgaaccttttgatgaagatcagcatacacaaattaca

[0093] aaagtcggctccggagcaaccaatttctctctgctcaagcaagccggagacgtcgaggaaaaccctgga

[0094] ccgatggaggagccgcagtcagatcctagcgtcgagccccctctgagtcaggaaacattttcagacctatg

[0095] gaaactacttcctgaaaacaacgttctgtcccccttgccgtcccaagcaatggatgatttgatgctgtccccgg

[0096] acgatattgaacaatggttcactgaagacccaggtccagatgaagctcccagaatgccagaggctgctcc

[0097] ccccgtggcccctgcaccagcagctcctacaccggcggcccctgcaccagccccctcctggcccctgtcat

[0098] cttctgtcccttcccagaaaacctaccagggcagctacggtttccgtctgggcttcttgcattctgggacagcc

[0099] aagtctgtgacttgcacgtactcccctgccctcaacaagatgttttgccaactggccaagacctgccctgtgc

[0100] agctgtgggttgattccacacccccgcccggcacccgcgtccgcgccatggccatctacaagcagtcaca

[0101] gcacatgacggaggttgtgaggcgctgcccccaccatgagcgctgctcagatagcgatggtctggcccctc

[0102] ctcagcatcttatccgagtggaaggaaatttgcgtgtggagtatttggatgacagaaacacttttcgacatagt

[0103] gtggtggtgccctatgagccgcctgaggttggctctgactgtaccaccatccactacaactacatgtgtaaca

[0104] gttcctgcatgggcggcatgaaccggaggcccatcctcaccatcatcacactggaagactccagtggtaat

[0105] ctactgggacggaacagctttgaggtgcgtgtttgtgcctgtcctgggagagaccggcgcacagaggaag

[0106] agaatctccgcaagaaaggggagcctcaccacgagctgcccccagggagcactaagcgagcactgcc

[0107] caacaacaccagctcctctccccagccaaagaagaaaccactggatggagaatatttcacccttcagatc

[0108] cgtgggcgtgagcgcttcgagatgttccgagagctgaatgaggccttggaactcaaggatgcccaggctg

[0109] ggaaggagccaggggggagcagggctcactccagccacctgaagtccaaaaagggtcagtctacctcc

[0110] cgccataaaaaactcatgttcaagacagaagggcctgactcagactga

[0111] hTERT promoter sequence, SEQ ID NO.2

[0112] agacaattcacaaacacagccctttaaaaaggcttagggatcactaaggggatttctagaagagcgacct

[0113] gtaatcctaagtatttacaagacgaggctaacctccagcgagcgtgacagcccagggagggtgcgaggc

[0114] ctgttcaaatgctagctccataaataaagcaatttcctccggcagtttctgaaagtaggaaaggttacatttaa

[0115] ggttgcgtttgttagcatttcagtgtttgccgacctcagctacagcatccctgcaaggcctcgggagacccag

[0116] aagtttctcgccccttagatccaaacttgagcaacccggagtctggattcctgggaagtcctcagctgtcctgc

[0117] ggttgtgccggggccccaggtctggaggggaccagtggccgtgtggcttctactgctgggctggaagtcgg

[0118] gcctcctagctctgcagtccgaggcttggagccaggtgcctggaccccgaggttgccctccaccctgtgcg

[0119] ggcgggatgtgaccagatgttggcctcatctgccagacagagtgccggggcccagggtcaaggccgttgt

[0120] ggctggtgtgaggcgcccggtgcgcggccagcaggagcgcctggctccatttcccaccctttctcgacggg

[0121] accgccccggtgggtgattaacagatttggggtggtttgctcatggtggggacccctcgccgcctgagaacc

[0122] tgcaaagagaaatgacgggcctgtgtcaaggagcccaagtcgcggggaagtgttgcagggaggcactc

[0123] cgggaggtcccgcgtgcccgtccagggagcaatgcgtcctcgggttcgtccccagccgcgtctacgcgcct

[0124] ccgtcctccccttcacgtccggcattcgtggtgcccggagcccgacgccccgcgtccggacctggaggca

[0125] gccctgggtctccggatcaggccagcggccaaagggtcgccgcacgcacctgttcccagggcctccacat

[0126] catggcccctccctcgggttaccccacagcctaggccgattcgacctctctccgctggggccctcgctggcg

[0127] tccctgcaccctgggagcgcgagcggcgcgcgggcggggaagcgcggcccagacccccgggtccgcc

[0128] cggagcagctgcgctgtcggggccaggccgggctcccagtggattcgcgggcacagacgcccaggacc

[0129] gcgcttcccacgtggcggagggactggggacccgggcacccgtcctgccccttcaccttccagctccgcct

[0130] cctccgcgcggaccccgccccgtcccgacccctcccgggtccccggcccagccccctccgggccctccc

[0131] agcccctccccttcctttccgcggccccgccctctcctcgcggcgcgagtttcaggcagcgctgcgtcctgct

[0132] gcgcacgtgggaagccctggccccggccacccccgcgat

[0133] CDC6 shRNA sequence, SEQ ID NO.3:

[0134] gatccccaggcacttgctaccagcaattcaagagattgctggtagcaagtgccttttttggaaa CMV sequence, SEQ ID NO.4:

[0135] Cgttacataacttacggtaaatggcccgcctggctgaccgcccaacgacccccgcccattgacgtcaata

[0136] atgacgtatgttcccatagtaacgccaatagggactttccattgacgtcaatgggtggagtatttacggtaaac

[0137] tgcccacttggcagtacatcaagtgtatcatatgccaagtacgccccctattgacgtcaatgacggtaaatgg

[0138] cccgcctggcattatgcccagtacatgaccttatgggactttcctacttggcagtacatctacgtattagtcatc

[0139] gctattaccatggtgatgcggttttggcagtacatcaatgggcgtggatagcggtttgactcacggggatttcc

[0140] aagtctccaccccattgacgtcaatgggagtttgttttggcaccaaaatcaacgggactttccaaaatgtcgta

[0141] acaactccgccccattgacgcaaatgggcggtaggcgtgtacggtgggaggtctatataagcagagctP16 sequence, SEQ ID NO.5:

[0142] atggagccggcggcggggagcagcatggagccttcggctgactggctggccacggccgcggcccggg

[0143] gtcgggtagaggaggtgcgggcgctgctggaggcgggggcgctgcccaacgcaccgaatagttacggt

[0144] cggaggccgatccaggtcatgatgatgggcagcgcccgagtggcggagctgctgctgctccacggcgcg

[0145] gagcccaactgcgccgaccccgccactctcacccgacccgtgcacgacgctgcccgggagggcttcctg

[0146] gacacgctggtggtgctgcaccgggccggggcgcggctggacgtgcgcgatgcctggggccgtctgccc

[0147] gtggacctggctgaggagctgggccatcgcgatgtcgcacggtacctgcgcgcggctgcggggggcacc

[0148] agaggcagtaaccatgcccgcatagatgccgcggaaggtccctcagacatccccgat PTEN sequence, SEQ ID NO.6:

[0149] atgacagccatcatcaaagagatcgttagcagaaacaaaaggagatatcaagaggatggattcgactta

[0150] gacttgacctatatttatccaaacattattgctatgggatttcctgcagaaagacttgaaggcgtatacaggaa

[0151] caatattgatgatgtagtaaggtttttggattcaaagcataaaaaccattacaagatatacaatctttgtgctga

[0152] aagacattatgacaccgccaaatttaattgcagagttgcacaatatccttttgaagaccataacccaccaca

[0153] gctagaacttatcaaacccttttgtgaagatcttgaccaatggctaagtgaagatgacaatcatgttgcagca

[0154] attcactgtaaagctggaaagggacgaactggtgtaatgatatgtgcatatttattacatcggggcaaattttta

[0155] aaggcacaagaggccctagatttctatggggaagtaaggaccagagacaaaaagggagtaactattccc

[0156] agtcagaggcgctatgtgtattattatagctacctgttaaagaatcatctggattatagaccagtggcactgttg

[0157] tttcacaagatgatgtttgaaactattccaatgttcagtggcggaacttgcaatcctcagtttgtggtctgccagc

[0158] taaaggtgaagatatattcctccaattcaggacccacacgacgggaagacaagttcatgtactttgagttcc

[0159] ctcagccgttacctgtgtgtggtgatatcaaagtagagttcttccacaaacagaacaagatgctaaaaaagg

[0160] acaaaatgtttcacttttgggtaaatacattcttcataccaggaccagaggaaacctcagaaaaagtagaaa

[0161] atggaagtctatgtgatcaagaaatcgatagcatttgcagtatagagcgtgcagataatgacaaggaatatc

[0162] tagtacttactttaacaaaaaatgatcttgacaaagcaaataaagacaaagccaaccgatacttttctccaa

[0163] attttaaggtgaagctgtacttcacaaaaacagtagaggagccgtcaaatccagaggctagcagttcaactt

[0164] ctgtaacaccagatgttagtgacaatgaacctgatcattatagatattctgacaccactgactctgatccaga

[0165] gaatgaaccttttgatgaagatcagcatacacaaattacaaaagtc

[0166] P53 sequence, SEQ ID NO.7:

[0167] atggaggagccgcagtcagatcctagcgtcgagccccctctgagtcaggaaacattttcagacctatggaa

[0168] actacttcctgaaaacaacgttctgtcccccttgccgtcccaagcaatggatgatttgatgctgtccccggacg

[0169] atattgaacaatggttcactgaagacccaggtccagatgaagctcccagaatgccagaggctgctccccc

[0170] cgtggcccctgcaccagcagctcctacaccggcggcccctgcaccagccccctcctggcccctgtcatctt

[0171] ctgtcccttcccagaaaacctaccagggcagctacggtttccgtctgggcttcttgcattctgggacagccaa

[0172] gtctgtgacttgcacgtactcccctgccctcaacaagatgttttgccaactggccaagacctgccctgtgcag

[0173] ctgtgggttgattccacacccccgcccggcacccgcgtccgcgccatggccatctacaagcagtcacagc

[0174] acatgacggaggttgtgaggcgctgcccccaccatgagcgctgctcagatagcgatggtctggcccctcct

[0175] cagcatcttatccgagtggaaggaaatttgcgtgtggagtatttggatgacagaaacacttttcgacatagtgt

[0176] ggtggtgccctatgagccgcctgaggttggctctgactgtaccaccatccactacaactacatgtgtaacagt

[0177] tcctgcatgggcggcatgaaccggaggcccatcctcaccatcatcacactggaagactccagtggtaatct

[0178] actgggacggaacagctttgaggtgcgtgtttgtgcctgtcctggggagagaccggcgcacagaggaagag

[0179] aatctccgcaagaaaggggagcctcaccacgagctgcccccagggagcactaagcgagcactgccca

[0180] acaacaccagctcctctccccagccaaagaagaaaccactggatggagaatatttcacccttcagatccgt

[0181] gggcgtgagcgcttcgagatgttccgagagctgaatgaggccttggaactcaaggatgcccaggctggga

[0182] aggagccaggggggagcagggctcactccagccacctgaagtccaaaaagggtcagtctacctcccgc

[0183] cataaaaaactcatgttcaagacagaagggcctgactcagactga

[0184] Example 2 Preparation and production process of multi-gene expression lentivirus

[0185] The hTERT-CDC6shRNA-CMV-P16-PTEN-P53 plasmid of Example 1 was transformed into Stbl3 competent cells to screen for canagliflozin-resistant monoclonal strains. The specific operation is as follows:

[0186] Take out competent cells Stbl3 (purchased from Thermo Fisher Scientific) and hTERT-CDC6shRNA-CMV-P16-PTEN-P53 plasmid from -80℃ refrigerator and thaw on ice. Take 1ug of plasmid and add it to competent cells, mix gently, and place it in ice for 25min. Quickly place the competent cells with added plasmid in a preheated 42℃ water bath for heat shock for 45 seconds, and place it in ice again for 2 minutes. Add 250ul LB liquid culture medium to the competent cells with added plasmid, 220rpm / min, 37℃, and recover for 1 hour. Dry the LB solid culture medium completely, absorb 50ul of the recovered transformation bacterial liquid, add the prepared LB solid culture medium, spread it evenly with a coating rod, and seal the culture dish with sealing film. Place the sealed LB solid culture medium upside down in a 37-degree incubator and culture for 12-16h to obtain a monoclonal strain with canagliflozin resistance.

[0187] The above monoclonal strain was shaken to obtain

[0188] hTERT-CDC6shRNA-CMV-P16-PTEN-P53 plasmid.

[0189] Select a typical single colony in a clean bench and place it in a 15 ml sterile centrifuge tube (containing 5 ml LB liquid medium) at 37°C, 220 rpm / min, and culture for 12-16 hours until the OD600 is 0.6-0.9. The next day, inoculate it into LB medium at a volume ratio of 1:100, culture it at 37°C, 220 rpm / min, and culture it for 16 hours to extract the plasmid.

[0190] The plasmid extracted in the previous step is packaged with the mixed packaging plasmids pLP1, pLP / VSVG, and pLP2 to obtain hTERT-CDC6shRNA-CMV-P16-PTEN-P53 lentivirus. The specific packaging operation is as follows:

[0191] The packaging cells are 293F cells, and the cell transfection density is 4.0-4.5×10 6 / ml.

[0192] Cell transfection steps: A: Use 5% opti-MEM to dilute the plasmid, the total amount of plasmid is 2.5ug / ml, and the ratio of packaging plasmid pLP1, pLP / VSVG, pLP2 to lentiviral plasmid is 1:1:1:2. B: Use 5% opti-MEM to dilute the plasmid, the amount of transfection reagent (purchased from Thermo Fisher Scientific, catalog number: A35348) is 6ul / ml, and it is placed at room temperature for 1min. The diluted plasmid is added to the diluted transfection reagent, placed at room temperature for 15min, and then added to 293F cells and mixed thoroughly. After 4h, 5% supplement and 4% enhancer are added, and the supernatant is collected after 56h. After purification by purification column, it is concentrated and replaced. First, it is concentrated 5 times, and then 3 times the volume of washing filter is used to replace the liquid (buffer: 20g / L sucrose is added to 0.02M phosphate buffer), and the lentivirus is obtained. After aliquoting, it is stored at -80℃.

[0193] The activity titer of lentivirus detected by QPCR was 2.23×10 6 TU / ml.

[0194] The steps for lentiviral activity detection are as follows:

[0195] 293T cells were used to detect the activity of lentivirus. The specific operation is as follows:

[0196] 1×10 5 293T cells were seeded into 6-well plates. After 24 hours, the cell density was B (approximately 2x10 5 ), 2 ml of culture medium per well. The next day, discard the culture medium and replace it with 1 ml / well of fresh DMEM culture medium. Gently drop 50 μl of lentivirus control (Shanghai Jikai Gene Technology) and 50 μl of virus into the wells, respectively, and make a blank control at the same time. After 24 hours of infection, replace the culture medium with 2 ml of fresh culture medium and continue to culture for 48 hours. Extract the cell genome to detect activity.

[0197] After the culture is completed, the cells are digested and the genome is extracted as follows:

[0198] The culture medium was aspirated, 1 ml of 1× PBS was added to each well to gently wash the cells and then discarded, the cells were digested with 0.5 ml of trypsin, and 1 ml of DMEM culture medium was added to resuspend the collected cells in a 1.5 ml centrifuge tube. Genomic DNA was extracted using a genome extraction kit (Tiangen Biochemical Technology (Beijing)), and the genomic DNA was eluted with 100 μl of Elution buffer; the dsDNA concentration and purity were detected by microplate reader.

[0199] Follow the steps to perform QPCR experiment to detect the activity of lentivirus. The specific steps are as follows:

[0200] Take the 293T cell reference gene DNA standard and dilute it 10× to a concentration of 1.0×10 8 copy-1.0×10 4 The target plasmid standard was diluted to a concentration of 1.0×10 8 copy-1.0×10 4 copy, and establish a standard curve.

[0201] Add 19 μl of the prepared PCR reaction system to the PCR reaction wells on the plate, and arrange the 293T cell reference gene DNA and target gene primers in an alternating pattern. Place the 293T cell reference gene DNA in rows A and B, and the target gene primers in rows C and D. Add 1 μl of DNA template to each reaction well, and set up a negative control in which enzyme-free water is used instead of the template;

[0202] The PCR reaction system was as follows, with two replicates for each sample:

[0203]

[0204]

[0205] PCR amplification procedure

[0206]

[0207] Results Analysis

[0208] Substitute the obtained Ct values ​​of the target gene and reference gene into the standard curve to obtain their respective copy numbers Q1 and Q2, and calculate the ratio of the target gene to the reference copy number Q1 / Q2. Then calculate the titer (transduction units per ml, TU / ml) according to the following formula:

[0209]

[0210] The 293T cell reference gene DNA primer probe sequences are as follows:

[0211] Forward primer TGC AGA TTT GGA CCT GCG AG(SEQ ID NO.8)

[0212] Reverse primer GAA TAG CCA AGG TGA GCG GC (SEQ ID NO.9)

[0213] Probe ACC TGA AGG CTC TGC GCG GAC TTG T(SEQ ID NO.10)

[0214] The target gene primer and probe sequences are as follows:

[0215] Forward primer GCT CCT TTC CGG GAC TTT CG(SEQ ID NO.11)

[0216] Reverse primer ATT GTC AGT GCC CAA CAG CC(SEQ ID NO.12)

[0217] Probe TCC CTA TTG CCA CGG CGG AAC TCA TCG(SEQ ID NO.13)

[0218] Example 3 Experiment of multi-gene expression lentivirus infecting tumor cells

[0219] Human thyroid cancer cells B-CPAP (papillary) were obtained from the Cell Resource Center of Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences. RPMI-1640 (purchased from Thermo Fisher Scientific) + 10% FBS (purchased from Gibco) culture medium was used. The culture flask was placed in a carbon dioxide incubator for culture under the conditions of 37°C and 5% CO2. After 24 hours of cell culture, the cell confluence rate was observed under a microscope at 80%-90%, and then the cells were passaged. After three passages, the cells were counted and plated.

[0220] Cell seeding and plating

[0221] Cell culture plate (6-well plate), culture volume is 2.5 ml / well, cell inoculation amount is 1.00×10 5 B-CPAP cells were trypsinized and resuspended in 10 ml RPMI-1640 complete medium. The cell count was 4.63 × 10 5 / ml, diluted 4.6 times, inoculated into 4 wells, 1ml B-CPAP cell suspension + 3.6ml RPMI-1640 complete medium, 2 wells were used for the experiment, and the remaining 2 wells were used as spare. 1ml diluted cell suspension + 1.5ml fresh medium was added to each well, and gently mixed. The culture conditions were: 37℃, 5% CO. Virus infection and cell observation.

[0222] The 6-well plates were labeled as B-CPAP blank and B-CPAP virus. Virus (2.23×10 6 TU) were infected for 24h, 48h, and 72h after infection. The cell status was observed under a microscope every day, and photos were taken and the medium was changed. The volume of the medium was 2.5ml. B-CPAP virus was added after the medium was changed (2.23×10 6The experiment was stopped after 72 h, and the cells were digested with trypsin, resuspended in 1 ml of RPMI-1640 complete medium, and counted using a cell counter (Thermo).

[0223] Comparison of cell status at 24-72 hours Figure 2 As shown, it can be seen that the cell morphology changes after virus infection, the cells do not stretch after attaching to the wall, and the cell growth is obviously inhibited.

[0224] Figure 3 This is the cell count 72 hours after infection, where the live cell density of the blank reached 5.69×10 5 / well, while the viable cell density after virus infection only reached 1.29×10 5 / well. The live cell density of blank was 1.00×10 5 Increased to 5.69×10 5 , an increase of 469%. The viable cell density after virus infection increased from 1.00×10 5 Increased to 1.29×10 5 , only increased by 29%. According to the tumor inhibition rate calculation formula T / C = (1-T / C) × 100, where T represents the virus group and C represents the blank group; by calculating the tumor inhibition ratio of the virus group relative to the blank group, the tumor inhibition rate can be calculated to be 77.33%.

[0225] Cell counting results:

[0226]

[0227] In summary, according to the cell growth conditions during the experiment, 72 hours after virus infection, the growth rate of virus-infected B-CPAP cells was significantly lower than that of B-CPAP blank cells, and the tumor inhibition rate reached 77.33%, showing an effective effect in inhibiting tumor cell growth.

Claims

1. A multi-gene expression lentivirus, characterized in that: The multi-gene expression lentivirus carries hTERT promoter, CDC6shRNA gene, CMV promoter, P16 gene, PTEN gene and P53 gene.

2. The multi-gene expression lentivirus according to claim 1, wherein the hTERT promoter sequence is SEQ ID NO.

2.

3. The multi-gene expression lentivirus according to claim 1, wherein the CDC6shRNA gene sequence is SEQ ID NO.

3. 4 . The multi-gene expression lentivirus according to claim 1 , wherein the CMV promoter sequence is SEQ ID NO.

4. 5 . The multi-gene expression lentivirus according to claim 1 , wherein the P16 gene sequence is SEQ ID NO.

5. The multi-gene expression lentivirus according to claim 1 , wherein the PTEN gene sequence is SEQ ID NO.

6.

7. The multi-gene expression lentivirus according to claim 1, wherein the P53 gene sequence is SEQ ID NO.

7.

8. The multi-gene expression lentivirus according to any one of claims 1 to 7, wherein the multi-gene expression lentivirus carries the hTERT-CDC6shRNA-CMV-P16-PTEN-P53 combination gene. 9 . The multi-gene expression lentivirus according to claim 8 , wherein the hTERT-CDC6shRNA-CMV-P16-PTEN-P53 combined gene sequence is SEQ ID NO.

1.

10. Use of the multi-gene expression lentivirus according to any one of claims 1 to 9 in the preparation of a drug for treating cancer. The use according to claim 10 , wherein the cancer is thyroid cancer.

12. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises the multi-gene expression lentivirus according to any one of claims 1 to 9.

13. The pharmaceutical composition according to claim 12, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.

14. The pharmaceutical composition according to claim 12 or 13, wherein the pharmaceutical composition is in the form of an injection.

15. The method for preparing a multi-gene expression lentivirus according to any one of claims 1 to 9, characterized in that: The method comprises: (1) inserting hTERT promoter, CDC6shRNA gene and CMV promoter, P16 gene, PTEN gene, and P53 gene sequences after the restriction site of the vector to obtain a plasmid; (2) transferring the plasmid into the expression strain, culturing and screening the successfully transferred strain; (3) shaking the successfully transferred strain obtained in step (2) to obtain the hTERT-CDC6shRNA-CMV-P16-PTEN-P53 multi-gene expression plasmid; (4) Packaging the multi-gene expression plasmid described in step (3) to obtain hTERT-CDC6shRNA-CMV-P16-PTEN-P53 multi-gene expression lentivirus.

Citation Information

Cited By

  • Application of CDC6shRNA based on U6 promoter in preparation of medicine for treating solid tumors

    CN120000678A

  • Lentivirus for treating cancers and preparation method therefor and use thereof

    WO2025209031A1

  • Lentivirus for treating craniopharyngioma, and preparation method therefor and use thereof

    WO2026056436A1